Evidence map›Paper›PMID 39608814›Full record

Observational studyLupus science & medicine2024

Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort.

Murray Urowitz, Mary E Georgiou, Zahi Touma, Jiandong Su, Juan Pablo Diaz-Martinez, Qinggong Fu, Roger A Levy, Kerry Gairy, Anne MacKinnon, Nicole Anderson and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Lupus science & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Murray UrowitzDivision of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0001-7506-9166
Mary E GeorgiouValue Evidence and Outcomes, GSK, Brentford, UK.ORCID 0000-0001-6225-2164
Zahi ToumaDivision of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0001-5177-2076
Jiandong SuDivision of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
Juan Pablo Diaz-MartinezDivision of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
Qinggong FuGlobal Medical Affairs, GSK, Collegeville, Pennsylvania, USA.
Roger A LevyGlobal Medical Affairs, GSK, Collegeville, Pennsylvania, USA roger.x.levy@gsk.com.ORCID 0000-0001-6393-6031
Kerry GairyValue Evidence and Outcomes, GSK, Brentford, UK.
Anne MacKinnonDivision of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
Nicole AndersonDivision of Rheumatology, University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
Patricia C JuliaoValue Evidence and Outcomes, GSK, Collegeville, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate modified versions of the Belimumab International Study in Lupus Nephritis (BLISS-LN) belimumab study primary efficacy renal response (mPERR) and complete renal response (mCRR) criteria (excluding mandatory corticosteroid tapering) as predictors of real-world, long-term renal outcomes among patients with lupus nephritis (LN).

methodsThis retrospective, observational study (GSK Study 212866) used deidentified data between 1970 and 2015 from the University of Toronto Lupus Cohort from adults diagnosed with systemic lupus erythematosus and biopsy-proven Class III±V, IV±V or V LN. At 24 months postbiopsy, patients were retrospectively indexed as responders/non-responders based on mPERR (estimated glomerular filtration rate (eGFR) ≤20% below biopsy value/≥60 mL/min/1.73 m

resultsOverall, 179 patients were included in the analysis (mPERR responders, n=128; non-mPERR responders, n=51). Most patients were female (87.2%); the mean (SD) age was 34.1 (11.3) years.Long-term renal survival was attained for 78.9% of mPERR responders and 60.8% of non-mPERR responders; achieving mPERR was associated with an increased likelihood of long-term renal survival versus not achieving mPERR (log-rank p=0.0119). Overall, 102 patients were mCRR responders, and 77 were non-mCRR responders. Long-term renal survival was attained for 80.4% of mCRR responders and 64.9% of non-mCRR responders; achieving mCRR was associated with an increased likelihood of long-term renal survival than not achieving mCRR (log-rank p=0.0259).

conclusionsAchieving mPERR or mCRR was associated with improved long-term renal survival, highlighting that these statuses are suitable predictors of long-term renal outcomes in patients with LN.

Indexed as

Glomerular Filtration RateImmunosuppressive AgentsKidneyLupus NephritisAdultAntibodies, Monoclonal, HumanizedBiopsyCreatinineDisease ProgressionFemaleHumansMaleMiddle AgedOntarioRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedbelimumabCreatinineImmunosuppressive AgentsLupus Erythematosus, SystemicLupus NephritisOutcome Assessment, Health Care

Identifiers

PMID39608814
PMCPMC11603717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.